格隆汇6月16日丨科济药业-B(02171.HK)发布公告，CT071(一种靶向GPRC5D的自体CAR-T细胞产品)用于治疗新诊断的多发性骨髓瘤(NDMM)的研究者发起的临床试验(NCT06407947)的研究结果已在第30届欧洲血液学协会(“EHA”)年会上进行展示。
CT071 IIT研究结果已于欧洲中部时间2025年6月13日18:30–19:30，在第30届EHA年会上进行壁报展示，标题为“靶向GPRC5D的CAR-T细胞疗法CT071用于高危新诊断的多发性骨髓瘤的I期研究”(“A phase I study of GPRC5D targeting CAR T-cell therapy CT071 for high-risk newly diagnosed multiple myeloma”)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.